

Calciphylaxis Diagnosed on Skin Biopsy in a Patient With Left Posterior Tibial Artery Stenosis

Shigeki Kuwasaki, MD; Hiroaki Kawano, MD;
Seiji Koga, MD; Kuniko Abe, MD;
Tsuyoshi Yonekura, MD; Satoshi Ikeda, MD;
Motoi Takenaka, MD; Koji Maemura, MD

An 84-year-old woman was admitted to identify the cause of painful skin ulceration of the left lower leg. She was under hemodialysis due to end-stage renal disease (ESRD) caused by nephrosclerosis (**Figure A**). She had been medicated with warfarin because of aortic valve replacement. Enhanced computed tomography showed stenosis of the left posterior tibial artery (**Figure B**). Laboratory data indicated mild anemia, hypoalbuminemia, hypercalcemia (adjusted calcium level, 11.1 mg/dL), and hypophosphatemia (phosphate, 1.7 mg/dL), with hyperparathyroidism (intact parathyroid hormone, 74.9 pg/mL). Skin perfusion pressure (SPP) was normal. Skin biopsy indicated severe stenosis of the small arteries with medial calcification compatible with calciphylaxis (**Figure C,D**). Subsequent debridement followed by a skin graft improved the ulceration in addition to treatment with alfacalcidol (0.25 μ g/day) and cinacalcet (12.5 mg/day; **Figure E**), and no calciphylaxis occurred over the 3-year follow-up period.

Calciphylaxis is a rare and often fatal complication of

ESRD that is characterized by painful skin ulceration and necrosis. Arteriosclerosis obliterans (ASO) is a frequent complication of ESRD, and it is also one of the causes of leg ulceration. In patients with leg skin ulcers who have both calciphylaxis and ASO, and in those with risk factors for the development of calciphylaxis, such as in patients on chronic hemodialysis, that is, warfarin and lower serum albumin,¹ SPP and skin biopsy may help to diagnose the cause of leg ulceration.

Disclosures

The authors declare no conflicts of interest.

Reference

1. Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y; Japanese Calciphylaxis Study Group. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. *Nephrol Dial Transplant* 2012; **27**: 1580–1584.

Received March 18, 2019; revised manuscript received May 23, 2019; accepted May 27, 2019; J-STAGE Advance Publication released online June 11, 2019 Time for primary review: 50 days

Department of Cardiovascular Medicine (S. Kuwasaki, H.K., S. Koga, T.Y., S.I., K.M.), Department of Dermatology (M.T.), Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Pathology, Nagasaki University Hospital, Nagasaki (K.A.), Japan

K.M. is a member of *Circulation Reports*' Editorial Team.

Mailing address: Hiroaki Kawano, MD, Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. E-mail: hkawano@nagasaki-u.ac.jp

ISSN-2434-0790 All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cr@j-circ.or.jp

